other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 4, 1998.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

- 1. German American Bancorp, Jasper, Indiana; to acquire 1st Bancorp, Vincennes, Indiana, and thereby indirectly acquire First Federal Bank, a Federal Savings Bank, Vincennes, Indiana, and thereby engage in the operation of a thrift, pursuant to § 225.28(b)(4)(ii) of Regulation Y; and Financial Services of Southern indiana Corp;, Vincennes, Indiana, and thereby engage in community development activities through making equity and debt investments in corporations or projects designed to promote community welfare, pursuant to § 225.28(b)(12)(i) of Regulation Y.
- B. Federal Reserve Bank of San Francisco (Maria Villanueva, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105-1579:
- 1. Wells Fargo & Company, San Francisco, California; Norwest Mortgage, Inc., Des Moines, Iowa; and Norwest Ventures, LLC, Des Moines, Iowa; to engage de novo in a joint venture through their subsidiary, Service Mortgage Group, LLC, Louisville, Kentucky, in residential mortgage lending, pursuant to § 225.28(b)(1) of Regulation Y.
- 2. Wells Fargo & Company, San Francisco, California; Norwest Mortgage, Inc., Des Moines, Iowa; and Norwest Ventures, LLC, Des Moines, Iowa; to engage de novo in a joint venture through their subsidiary, Academy Financial Services, LLC, Alpharetta, Georgia, in residential mortgage lending, pursuant to § 225.28(b)(1) of Regulation Y.

Board of Governors of the Federal Reserve System, November 16, 1998.

Robert deV. Frierson.

Associate Secretary of the Board. [FR Doc. 98–31020 Filed 11–9–8; 8:45 am] BILLING CODE 6210–1–F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10:00 a.m., Wednesday, November 25, 1998.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551. STATUS: Closed.

MATTERS TO BE CONSIDERED:

- 1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
- 2. Any matters carried forward from a previously announced meeting. CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: November 18, 1998.

Robert deV. Frierson,

Associate Secretary of the Board. [FR Doc. 98–31188 Filed 11–18–98; 11:03 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Center for HIV, STD and TB Prevention (NCHSTP), of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

Name: HIV Prevention for Gay Men of Color Consultation.

Times and Dates: 9 a.m.–5 p.m., December 2, 1998. 9 a.m.–5 p.m., December 3, 1998.

Place: The Sheraton Colony Square Hotel Midtown Atlanta, 188 14th Street, N. E., Atlanta, Georgia 30361.

Status: Open to the public for observation and comment, limited only by space available. The meeting room accommodates approximately 65 people.

Purpose: The purpose of this meeting is to provide a forum for consultation and discussion among Gay Men of Color (African Americans, Latinos, Asian and Pacific Islanders, and Native Americans). Participants will represent non-governmental organizations and the Division of HIV/AIDS Prevention (DHAP), NCHSTP. The discussion will address challenges faced by organizations in developing/implementing HIV/AIDS prevention interventions for gay men of color; and examine issues related to organizational capacity building for organizations serving gay men of color.

Matters To Be Discussed: HIV/AIDS surveillance activities related to gay men of color; and analyses and trend data for gay men of color, e.g., geographical trends, data regarding men having sex with other men vs. other populations at risk, etc.

Agenda items are subject to change as priorities dictate.

Contacts for More Information: Janet Cleveland or Yulonda Williams, Division of HIV/AIDS Prevention—Intervention Research and Support, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, m/s E-35, Atlanta, Georgia 30333, telephone 404/639–5200.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: November 16, 1998.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–31021 Filed 11–19–98; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration [Docket No. 97C-0171]

Closure Medical Corp.; Withdrawal of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to future filing, of a color additive petition (CAP 7C0250) proposing that the color additive regulations be amended to

provide for the safe use of D&C Violet No. 2 to color 2-octyl cyanoacrylate topical tissue adhesives.

FOR FURTHER INFORMATION CONTACT: Ellen M. Waldron, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3089.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of May 1, 1997 (62 FR 23781), FDA announced that a color additive petition (CAP 7C0250) had been filed by Closure Medical Corp., 5265 Capital Blvd., Raleigh, NC 27616 (currently 5250 Greens Dairy Rd., Raleigh, NC 27616). The petition proposed to amend the color additive regulations in § 74.3602 D&C Violet No. 2 (21 CFR 74.3602) to provide for the safe use of D&C Violet No. 2 to color 2-octyl cyanoacrylate topical tissue adhesives.

With the passage of the Medical Device Amendments of 1976 (Pub. L. 94–295), Congress mandated the listing of color additives for use in medical devices when the color additive in the device comes into direct contact with the body for a significant period of time (21 U.S.C. 379e(a)). Since the filing of this petition, the agency has determined that the proposed use of the subject topical tissue adhesives, and therefore, any color additive used in these adhesives, would not contact the body for a significant period of time (Ref. 1). Consequently, the petitioned use of D&C Violet No. 2 is exempt from the statutory listing requirement. Therefore, Closure Medical Corp. has now withdrawn the petition without prejudice to a future filing (21 CFR 71.6(c)(2)) (Ref. 2).

The agency received two comments on the safety of D&C Violet No. 2 in response to the notice of filing for this petition. Arts, Crafts & Theater Safety, Inc. (ACTS) commented that D&C Violet No. 2 could possibly be a carcinogen, based on studies of other anthraguinone dyes and structurally related compounds that concluded those substances were reasonably anticipated to be human carcinogens. They stated that the petition should be denied unless D&C Violet No. 2 is studied for cancer effects and found to show no evidence of carcinogenicity. In response to ACTS" comment, Flamm Associates commented that in addition to a consideration of the general chemical class of a substance, other structural features need to be evaluated in determining the carcinogenic potential of a substance. They further stated that D&C Violet No. 2 has been tested for carcinogenicity and found to be noncarcinogenic.

The agency concludes that, although the subject petition is being withdrawn, the safety of the currently approved uses of D&C Violet No. 2 (21 CFR 74.1602, 74.2602 and 74.3602) is supported by an extensive body of toxicity testing data and that the comments provide no basis for a safety concern.

References

The following references have been placed on display in the Dockets Management Branch (HFA–305), 5630 Fishers Lane, Rockville, MD 20852 and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday.

1. Memorandum from Office of Device Evaluation, Program Operations Staff (Center for Devices and Radiological Health, FDA), to Division of Petition Control (Center for Food Safety and Applied Nutrition, FDA), concerning "CAP 7C0250", dated October 23, 1998.

2. Letter from Hyman, Phelps & McNamara, P.C., to Office of Premarket Approval (FDA), dated August 25, 1998.

Dated: November 3, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98-31030 Filed 11-19-98; 8:45 am] BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration [Docket No. 98N-0378]

Agency Information Collection Activities; Announcement of OMB Approval; Color Additive Certification Requests and Recordkeeping

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Color Additive Certification Requests and Recordkeeping" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA). FOR FURTHER INFORMATION CONTACT: Margaret R. Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223. SUPPLEMENTARY INFORMATION: In the Federal Register of September 1, 1998 (63 FR 46461), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the

PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0216. The approval expires on October 31, 2001.

Dated: November 12, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–31031 Filed 11–19–98; 8:45 am] BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the teleconference meeting of the Advisory Committee for Women's Services of the Substance Abuse and Mental Health Services Administration (SAMHSA) in December 1998.

The meeting of the Advisory Committee for Women's Services will include a discussion of the role and responsibilities of the Advisory Committee in providing advice to SAMHSA, and policy and program issues relating to women's substance abuse and mental health service needs at SAMHSA, including the Fiscal Year 1999 budget and SAMHSA's FY 1999 Knowledge Development and Application Grants.

Public comments are welcome. Please communicate with the individual listed as Contact below to make arrangements to comment or to request special accommodations for persons with disabilities.

A summary of the meeting and/or a roster of committee members may be obtained from: Pamela M. Perry, Executive Secretary, Advisory Committee for Women's Services, Women, Children and Families Team, SAMHSA, Parklawn Building, Room 13–99, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443–7625, e-mail: pperry@samhsa.gov.

Substantive information may be obtained from the contact whose name and telephone number is listed below.

Committee Name: Advisory Committee for Women's Services.

Meeting Date(s): December 18, 1998.